Jieli Zhou

ORCID: 0000-0002-7616-5982 · 2 papers in corpus
observational 2024
Frontiers in oncology ·doi:10.3389/fonc.2024.1390820

BACKGROUND: Pre-clinical studies showed the anti-tumor mechanisms of PARP inhibitors (PARPi) and platinum have some crossover and overlap in the DNA damage repair pathway, patients who respond to platinum-based chemotherapy are also more li…

2024
·doi:10.1007/s12262-024-04072-3